🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07799584
Recruiting Not applicable

Temporal Interference Stimulation Combined With Tai Chi for Mild Cognitive Impairment

NCT07799584 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai University of Sport
Phase
Not applicable
Started
2026-08-25
Last updated
2026-09-02

Condition(s) studied

Mild Cognitive Impairment (MCI)

Investigational drug(s) / intervention(s)

Active Transcranial Temporal Interference StimulationPlacebo Transcranial Temporal Interference StimulationTai Chi Training

Active Transcranial Temporal Interference Stimulation: Active tTIS delivered via surface electrodes targeting the hippocampus. Parameters: 2 mA baseline-to-peak intensity, 20-minute duration with 30-second ramp-up and ramp-down. The stimulation protocol is individualized based on each participant's T1-weighted structural MRI using finite element modeling to optimize electric field distribution to the hippocampal target. Stimulation will be administered three times per week for 8 weeks.

Placebo Transcranial Temporal Interference Stimulation: Placebo stimulation delivered using the same electrode placement and parameters as active stimulation. To mimic the sensory experience without effective neuromodulation, active current is delivered only during the 30-second ramp-up and ramp-down periods. During the 20-minute stimulation period, no current is delivered. Participants are unable to distinguish sham from active stimulation based on sensation. Sham stimulation will be administered three times per week for 8 weeks.

Tai Chi Training: Participants will receive standardized Tai Chi training for approximately 60 minutes per session, three sessions per week for 8 weeks. The same Tai Chi training protocol will be provided to participants in both study arms.

Study summary

This study aims to evaluate whether individualized hippocampal transcranial temporal interference stimulation (tTIS) combined with Tai Chi training can improve cognitive function and dual-task performance in individuals with mild cognitive impairment. Participants will be randomly assigned to receive either active or sham individualized tTIS combined with Tai Chi training for 8 weeks. The study will also investigate changes in brain structure and function using neuroimaging and assess whether the intervention effects are maintained during follow-up.

Eligibility

Sex
ALL
Min age
60 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age 60-80 years * Community-dwelling * Montreal Cognitive Assessment (MoCA) score \< 26 * Clinical Dementia Rating (CDR) score = 0.5 * Activities of Daily Living (ADL) score \< 26 (largely intact daily function) * Does not meet criteria for dementia diagnosis (based on DSM-5 or NIA-AA criteria) * No contraindications for MRI examination (no metallic implants, no claustrophobia) * Able to provide written informed consent Exclusion Criteria: * Neurological conditions that may cause cognitive decline (e.g., cerebrovascular disease, encephalitis, Parkinson's disease, Huntington's disease) * Severe visual, auditory, or language impairments preventing completion of neuropsychological assessments * Severe depression (Geriatric Depression Scale \> 10) or other major psychiatric disorders * History of seizures or epilepsy * Previous deep brain stimulation or electroconvulsive therapy within 6 months * Alcohol or substance dependence * Concurrent participation in another interventional clinical trial * Contraindications for non-invasive brain stimulation: electronic or ferromagnetic implants, non-MRI compatible metal implants, history of seizures, pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shanghai University of Sport Shanghai Shanghai Municipality Recruiting

More Shanghai University of Sport trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07799584 on ClinicalTrials.gov ↗ ← All trials in China